SYS6043 / CSPC Pharma - LARVOL DELTA

Phase I/II clinical study of SYS6043 combined with PD-1/PD-L1 inhibitor ± chemotherapy in the treatment of advanced solid tumor participants (ChiCTR) - P1/2 | N=622 | Not yet recruiting | Sponsor: Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

New P1/2 trial • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

SYS6043, a B7-H3 targeting antibody-drug conjugates in patients with advanced gynecologic cancers: a phase 1/2, first-in-human study (SGO 2026) - No abstract available

Clinical • First-in-human • Metastases • P1/2 data • Gynecologic Cancers • Oncology

A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=444 | Recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

New P1/2 trial • Solid Tumor

SYS6043 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. (HKEXnews) - "The board of directors (the 'Board') of CSPC Pharmaceutical Group Limited...is pleased to announce that the Investigational New Drug (IND) application for SYS6043 (Antibody-Drug Conjugate) (the 'Product') developed by the Group has been approved by the U.S. Food and Drug Administration (FDA) to conduct clinical trial in the U.S....The indication for this approval is advanced/metastatic solid tumors, and the Product is expected to be indicated for the treatment of small cell lung cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, prostate cancer and hepatocellular carcinoma."

IND • Esophageal Squamous Cell Carcinoma • Hepatocellular Cancer • Prostate Cancer • Small Cell Lung Cancer • Squamous Cell Carcinoma of Head and Neck